Bridgebio Pharma Inc holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 769,301 | $26,594,733 | 0.29% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2025 |
| June 30, 2025 | 535,763 | $23,134,261 | 0.21% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2025 |
| Sept. 30, 2025 | 659,633 | $34,261,333 | 0.31% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 14, 2025 |
| Dec. 31, 2025 | 826,131 | $63,190,753 | 0.67% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 17, 2026 |
| March 31, 2026 | 957,989 | $71,140,263 | 0.73% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2026 |
| June 30, 2026 | 1,373,057 | $102,265,291 | 0.95% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.